Xtant Medical Holdings, Inc.
New York Stock Exchange AmericanCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Sean E. Browne
- Full Time Employees
- 217
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 664 Cruiser Lane Belgrade MT United States of America 59714
- IPO Date
- Jul 1, 2010
- CIK
- 0001453593
- Website
- xtantmedical.com
- Similar Companies
- Business
- Xtant Medical Holdings, Inc. Xtant Medical Holdings, Inc. (NYSE American: XTNT) develops, manufactures, and commercializes regenerative biologics and spinal implant systems for orthopedic, spinal, neurological, and wound care procedures; its core orthobiologics portfolio spans all five major U.S. market categories including demineralized bone matrix (DBM) in putty, paste, and fiber forms, traditional and cellular allografts such as Trivium and OsteoVive Plus, synthetic bone grafts like NanOss, marrow-derived growth factors including OsteoFactor Pro launched in May 2025, and amniotic membrane products like SimpliMax and SimpliGraft for advanced wound care and surgical repair; complementary fixation systems cover cervical, thoracolumbar, sacroiliac joint, and interbody approaches for spinal fusion in complex deformity and degenerative cases. Headquartered in Belgrade, Montana with additional facilities in Ohio, the company operates as an accredited tissue bank with vertically integrated capabilities from donor procurement and processing to distribution, serving U.S. surgeons through over 670 independent distributors and 450 integrated delivery network contracts with major group purchasing organizations; founded in 2000, Xtant Medical focuses on the $2.5 billion orthobiologics segment and adjacent $12 billion wound care market, emphasizing innovation backed by 25 years of biologics experience and a pipeline including FibreX DBM fibers, NanOss 2.0 synthetics, and Ematrix collagen platforms through 2026. In July 2025, Xtant Medical announced definitive agreements to sell its non-core Coflex and CoFix spinal implant systems along with international Paradigm Spine operations to Companion Spine for approximately $19.2 million, expected to close by year-end to streamline focus on higher-margin orthobiologics, reduce long-term debt, and enhance liquidity; this follows the April 2025 secondary private sale of 73.1 million shares by OrbiMed Advisors to investors led by Nantahala Capital Management, terminating prior investor rights and providing strategic flexibility; recent product launches like OsteoFactor Pro completed its growth factor offerings, while Q2 2025 results showed 18% revenue growth to $35.4 million, positive net income of $3.6 million, and gross margins expanding to 69%, with full-year 2025 guidance raised to $131-135 million driven by 100% organic biologics growth.
Xtant Medical Q1 Earnings Call Highlights
Xtant Medical Holdings, Inc. (XTNT) Q1 2026 Earnings Call Transcript
Xtant Medical Reports First Quarter 2026 Financial Results
Xtant Medical to Announce First Quarter 2026 Financial Results on May 13, 2026
Xtant Medical Expands Trivium™ Portfolio with the Commercial Launch of Trivium™ Shaped
Xtant Medical and Dilon Technologies Announce Exclusive U.S. Distribution Agreement for Dilon's HEMOBLAST® Bellows Product
Xtant Medical and Montana Governor's Office of Community Service Announce Support for "Threshold of Life" Memorial
Xtant Medical Holdings, Inc. (XTNT) Q4 2025 Earnings Call Transcript
Xtant Medical Reports Fourth Quarter and Full-Year 2025 Financial Results
Xtant Medical to Announce Fourth Quarter and Full Year 2025 Financial Results on March 31, 2026
Xtant Medical Finalizes Companion Spine Transactions
Xtant Medical to Participate in the Canaccord Genuity 2026 Musculoskeletal Conference
AWM Investment Company Inc. Takes $4.88 Million Position in Xtant Medical Holdings, Inc. $XTNT
Xtant Medical Announces Commercial Launch of its Next-Generation nanOss Strata™ Synthetic Bone Graft
Xtant Medical Completes Sale of its Coflex® Assets and Paradigm OUS Businesses to Companion Spine
Xtant Medical Holdings, Inc. (XTNT) Q3 2025 Earnings Call Transcript
Xtant Medical Reports Third Quarter 2025 Financial Results
Xtant Medical Announces Commercial Launch of CollagenX™
Xtant Medical to Announce Third Quarter 2025 Financial Results on November 11, 2025
Xtant Medical to Participate in the H.C. Wainwright 27th Annual Global Investment Conference